TREATMENT OF PATIENTS DIAGNOSED WITH PANCREATIC DUCTAL ADENOCARCINOMA USING MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 27, 2025
app pub date -
Sep 4, 2024
filing date -
Sep 4, 2024
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention relates to the field of immunotherapy of cancer, in particular pancreatic ductal adenocarcinoma (PDAC). More specifically, the present invention provides means and methods for treatment of a population of PDAC patients suffering from PDAC tumors which express wild-type KRAS, HRAS or NRAS. The means and methods of the invention envisaged administration of an anti-EGFR antibody or antigen-binding fragment or peptide thereof to the patients. Means and methods for selecting patients and tumors for their responsiveness to the treatment are also provided herein.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully